We describe the use of tin-mesoporphyrin (SnMP) in the treatment of an infant with Rh hemolytic disease. The infant's hyperbilirubinemia responded to phototherapy but every time the phototherapy was discontinued, the serum bilirubin rebounded and repeat phototherapy was necessary. A single intramuscular dose of SnMP on day 18 eliminated the need for further phototherapy and allowed us to discharge this infant.
Introduction
Tin-mesoporphyrin (SnMP) inhibits the activity of heme oxygenase, the rate-limiting enzyme in the heme catabolic pathway, and it suppresses bilirubin formation. 1 We document the use of SnMP in a male infant with refractory hyperbilirubinemia due to Rh hemolytic disease who required repeated phototherapy, prolonging his hospital stay. A single intramuscular dose of SnMP eliminated the need for further phototherapy and allowed us to discharge this infant.
Case report
This 35 3/7 week gestation male, birth weight 2717 g, was born to a G2P0010, 34 year old, blood group O, Rh D-negative mother. While traveling, 6 years before this pregnancy, she had an ectopic pregnancy but did not receive Rh immune globulin and, during this pregnancy, was diagnosed with Rh D sensitization. The Apgar scores were 6 and 8 at 1 and 5 min, respectively. The infant's blood type was O Rh D-positive and the direct antiglobulin test 4 þ positive, cord blood total serum bilirubin (TSB) 2.4 mg dl À1 , hemoglobin 17.7 g dl À1 , reticulocyte count 392 bil per l (120 to 379). At age 3 h the TSB was 3.5 mg dl À1 and intensive phototherapy was started using the Bili-Bassinet (Natus Medical, San Carlos, CA, USA). This device consists of two special blue fluorescent (F20T12BB) overhead phototherapy lights and special blue tubes beneath the infant. Irradiance was measured during each nursing shift with the BiliBlanket Meter II (Ohmeda, GE Healthcare, Fairfield, CT, USA, spectral range 400 to 520 nm, peak 450 nm) and averaged 39±7.4 mW cm À2 nm À1 at the level of the infant's abdomen. Irradiance measured directly over the lower tubes was B72 mW cm À2 nm À1 . The subsequent course of his TSB levels and the relevant interventions are shown in the figure. As illustrated, the TSB responded promptly to phototherapy, but every time the phototherapy was discontinued, the TSB rebounded. He was breastfed, thriving and otherwise perfectly healthy. On day 13 he received 500 mg kg À1 intravenous immune globulin and was started on 20 mg kg À1 per day ursodeoxycholic acid. (Although there was no evidence of cholestasis, ursodeoxycholic acid has been used to maximize bile flow in an attempt to decrease TSB in infants with severe hyperbilirubinemia 2 ). By the age of 16 days, his hemoglobin had fallen to 8.3 g dl À1 , he received a transfusion of 15 ml kg À1 packed red blood cells and his hemoglobin increased to 10.7 g dl À1 . The direct bilirubin levels ranged from 0.3 to 0.5 mg dl
À1 . An Investigational New Drug application for the use of SnMP was submitted to the FDA and approved, and the drug, Stanate, was supplied by the manufacturer (InfaCare Pharmaceutical Corp, Trevose, PA, USA). On day 18, following parental informed consent, 4.5 mg kg À1 (6 mmole kg À1 ) SnMP was administered intramuscularly and phototherapy continued for 18 h. On day 19, phototherapy was discontinued and he was discharged at age 20 days with a TSB of 5.5 mg dl À1 , hemoglobin 11.3 g dl
À1
. He was followed as an outpatient and on day 32 his hemoglobin was 8.4 g dl À1 , TSB 7.1 mg dl À1 . He did not require additional blood transfusions and at age 3 months his TSB was 1.2 mg dl À1 , direct bilirubin 0.3 mg dl À1 , hemoglobin 10.9 g dl
.
Discussion
To date, SnMP has been administered to more than 800 infants in clinical trials, 1, [3] [4] [5] [6] [7] [8] [9] [10] [11] and the only side effect, observed occasionally, has been a transient, spontaneously resolving, erythematous rash. The efficacy of SnMP in controlling neonatal hyperbilirubinemia has been demonstrated in both hemolytic 7, 8 and non-hemolytic conditions 5, 9 and it has been used to prevent the need for exchange transfusion in Jehovah's Witness' infants. 10 Before phototherapy was introduced, it is likely that this infant would have received an exchange transfusion and been discharged by age 4 to 5 days. The availability of intensive phototherapy led to a prolonged hospitalization with no clear end in sight. In infants who receive phototherapy before discharge from the hospital, the risk of significant rebound ranges from 8 to 15% 12, 13 and is likely to be higher in infants who have documented, direct antiglobulin test-positive hemolytic disease. The magnitude of the rebound in this infant (Figure 1 ) even after 15 days of intensive phototherapy and the declining hemoglobin levels, reflect ongoing hemolysis. Discontinuing phototherapy is always a matter of trial and error and we do not know whether continuing phototherapy until the TSB declined further might have helped to shorten the hospital stay. But given the infant's response to each course of phototherapy, it seemed appropriate to discontinue it, as illustrated, to see if discharge was possible. Ultimately, one dose of SnMP eliminated the need for further phototherapy and allowed us to discharge this infant. We believe this is the first case documenting the efficacy of SnMP in preventing the need for repeated phototherapy in an infant with Rh hemolytic disease.
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